For Healthcare ProfessionalsIntended for US Audiences

Clinical Performance

Only ADVATE [Antihemophilic Factor (Recombinant)] has 12 years of experience in the real world as a latest-generation plasma/albumin-free recombinant factor VIII2

  • More than 20 billion IUs distributed worldwide3
  • Proven record of clinical performance and safety profile4-9
  • Extensively studied recombinant factor VIII treatment4-10
  • Third-generation full-length molecule, similar to the factor VIII that occurs naturally in the body1,2


ADVATE is the only FVIII with health-related quality-of-life results*11

See data

* Based on a list of other drugs and biologics approved with health-related quality-of-life information in the labeling, as of November 2014.11


Learn how the two treatment regimens may affect the timing of when factor VIII levels are at their highest and lowest after infusing.

Read the data


Results of published clinical studies for ADVATE.

See the results
Read these case studies about hemophilia patients using prophylaxis treatment.

Case Studies

Check out how patients, who aspired to achieve zero bleeds with prophylactic treatment, realized results.

Read the case studies